The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

References

• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl1):74–81.
   Web of Science ®Google Scholar
• Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833–8.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73 e1.
   PubMed Web of Science ®Google Scholar
• Duberg AS, Blach S, Falconer K, Kaberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50:233–44.
   PubMed Web of Science ®Google Scholar
• Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe. J Med Virol. 2016;88:2157–69.
   PubMed Web of Science ®Google Scholar
• Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvag BK, et al. Molecular characterization of HCV in a Swedish county over 8 years (2002–2009) reveals distinct transmission patterns. Infect Ecol Epidemiol. 2016;6:30670.
   PubMedGoogle Scholar
• Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000–2005 update. Ann Pharmacother. 2006;40:74–82.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132–42 e4.
   PubMed Web of Science ®Google Scholar
• Dubin PH, Sclair SN, Rico R, Boehme AK, Chen EY, Martin P, et al. Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir. Dig Dise Sci. 2015;60:272–4.
   PubMed Web of Science ®Google Scholar
• Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, et al. Final results of the telaprevir access program: FibroScan values predict safety and efficacy in hepatitis C patients with advanced fibrosis or cirrhosis. PLoS One. 2015;10:e0138503.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol. 2011;55:692–701.
   PubMed Web of Science ®Google Scholar
• Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders. Springerplus. 2015;4:357.
   PubMed Web of Science ®Google Scholar
• About F, Oudot-Mellakh T, Niay J, Rabiega P, Pedergnana V, Duffy D, et al. Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20-CUPIC Study. PLoS One. 2015;10:e0145105.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
   PubMed Web of Science ®Google Scholar
• Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–91.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Wedemeyer H, Cloherty G, Cohen DE, Chevaliez S, Herman C, et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods. 2015;214:29–32.
   PubMed Web of Science ®Google Scholar
• Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol. 2013;19:8940–8.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014;21:229–40.
   PubMed Web of Science ®Google Scholar
• Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012;26:487–503.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
   PubMed Web of Science ®Google Scholar
• Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12:717–28.
   PubMed Web of Science ®Google Scholar
• Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64–71.
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434–41.
   PubMed Web of Science ®Google Scholar
• Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis. 2012;44:502–21.
   PubMed Web of Science ®Google Scholar
• Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50.
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslen L, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12–17.
   PubMed Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–12 e1.
   PubMed Web of Science ®Google Scholar
• Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010;54:5288–97.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65.
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol. 2015;65:50–3.
   PubMed Web of Science ®Google Scholar
• Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxi A, et al. An open-label trial of 12-week simeprevir plus peginterferon/ribavirin (PR) in treatment-naive patients with hepatitis C virus (HCV) genotype 1 (GT1). PLoS One. 2016;11:e0158526.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2015;62:286–93.
   PubMed Web of Science ®Google Scholar
• Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014;39:1213–24.
   PubMed Web of Science ®Google Scholar
• Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007;61:999–1014.
   PubMed Web of Science ®Google Scholar